Biovail Corp said on Friday it is being investigated by a U.S. federal grand jury in Boston in connection with the 2003 commercial launch of its Cardizem LA heart drug, and analysts speculated the probe might delve into whether physicians were paid to prescribe the treatment. The company would not elaborate on the exact nature of the investigation, and officials in Boston would not comment.
“We’re not confirming or denying a grand jury investigation,” said Christina Diiorio-Sterling, a spokeswoman at the United States Attorney’s Office, District of Massachusetts.